Dolutegravir and Its Combination Drug Market - Global Outlook and Forecast 2023-2028

Report ID: 1369907 | Published Date: Jan 2025 | No. of Page: 64 | Base Year: 2024 | Rating: 4.6 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Introduction to Research & Analysis Reports
    1.1 Dolutegravir and Its Combination Drug Market Definition
    1.2 Market Segments
        1.2.1 Market by Type
        1.2.2 Market by Application
    1.3 Global Dolutegravir and Its Combination Drug Market Overview
    1.4 Features & Benefits of This Report
    1.5 Methodology & Sources of Information
        1.5.1 Research Methodology
        1.5.2 Research Process
        1.5.3 Base Year
        1.5.4 Report Assumptions & Caveats
2 Global Dolutegravir and Its Combination Drug Overall Market Size
    2.1 Global Dolutegravir and Its Combination Drug Market Size: 2021 VS 2028
    2.2 Global Dolutegravir and Its Combination Drug Market Size, Prospects & Forecasts: 2017-2028
    2.3 Key Market Trends, Opportunity, Drivers and Restraints
        2.3.1 Market Opportunities & Trends
        2.3.2 Market Drivers
        2.3.3 Market Restraints
3 Company Landscape
    3.1 Top Dolutegravir and Its Combination Drug Players in Global Market
    3.2 Top Global Dolutegravir and Its Combination Drug Companies Ranked by Revenue
    3.3 Global Dolutegravir and Its Combination Drug Revenue by Companies
    3.4 Top 3 and Top 5 Dolutegravir and Its Combination Drug Companies in Global Market, by Revenue in 2021
    3.5 Global Companies Dolutegravir and Its Combination Drug Product Type
    3.6 Tier 1, Tier 2 and Tier 3 Dolutegravir and Its Combination Drug Players in Global Market
        3.6.1 List of Global Tier 1 Dolutegravir and Its Combination Drug Companies
        3.6.2 List of Global Tier 2 and Tier 3 Dolutegravir and Its Combination Drug Companies
4 Market Sights by Product
    4.1 Overview
        4.1.1 by Type - Global Dolutegravir and Its Combination Drug Market Size Markets, 2021 & 2028
        4.1.2 Dolutegravir
        4.1.3 Abacavir/Dolutegravir/Lamivudine
        4.1.4 Dolutegravir/Rilpivirine
    4.2 By Type - Global Dolutegravir and Its Combination Drug Revenue & Forecasts
        4.2.1 By Type - Global Dolutegravir and Its Combination Drug Revenue, 2017-2022
        4.2.2 By Type - Global Dolutegravir and Its Combination Drug Revenue, 2023-2028
        4.2.3 By Type - Global Dolutegravir and Its Combination Drug Revenue Market Share, 2017-2028
5 Sights by Application
    5.1 Overview
        5.1.1 By Application - Global Dolutegravir and Its Combination Drug Market Size, 2021 & 2028
        5.1.2 Hospital
        5.1.3 Clinic
        5.1.4 Drug Center
        5.1.5 Other
    5.2 By Application - Global Dolutegravir and Its Combination Drug Revenue & Forecasts
        5.2.1 By Application - Global Dolutegravir and Its Combination Drug Revenue, 2017-2022
        5.2.2 By Application - Global Dolutegravir and Its Combination Drug Revenue, 2023-2028
        5.2.3 By Application - Global Dolutegravir and Its Combination Drug Revenue Market Share, 2017-2028
6 Sights by Region
    6.1 By Region - Global Dolutegravir and Its Combination Drug Market Size, 2021 & 2028
    6.2 By Region - Global Dolutegravir and Its Combination Drug Revenue & Forecasts
        6.2.1 By Region - Global Dolutegravir and Its Combination Drug Revenue, 2017-2022
        6.2.2 By Region - Global Dolutegravir and Its Combination Drug Revenue, 2023-2028
        6.2.3 By Region - Global Dolutegravir and Its Combination Drug Revenue Market Share, 2017-2028
    6.3 North America
        6.3.1 By Country - North America Dolutegravir and Its Combination Drug Revenue, 2017-2028
        6.3.2 US Dolutegravir and Its Combination Drug Market Size, 2017-2028
        6.3.3 Canada Dolutegravir and Its Combination Drug Market Size, 2017-2028
        6.3.4 Mexico Dolutegravir and Its Combination Drug Market Size, 2017-2028
    6.4 Europe
        6.4.1 By Country - Europe Dolutegravir and Its Combination Drug Revenue, 2017-2028
        6.4.2 Germany Dolutegravir and Its Combination Drug Market Size, 2017-2028
        6.4.3 France Dolutegravir and Its Combination Drug Market Size, 2017-2028
        6.4.4 U.K. Dolutegravir and Its Combination Drug Market Size, 2017-2028
        6.4.5 Italy Dolutegravir and Its Combination Drug Market Size, 2017-2028
        6.4.6 Russia Dolutegravir and Its Combination Drug Market Size, 2017-2028
        6.4.7 Nordic Countries Dolutegravir and Its Combination Drug Market Size, 2017-2028
        6.4.8 Benelux Dolutegravir and Its Combination Drug Market Size, 2017-2028
    6.5 Asia
        6.5.1 By Region - Asia Dolutegravir and Its Combination Drug Revenue, 2017-2028
        6.5.2 China Dolutegravir and Its Combination Drug Market Size, 2017-2028
        6.5.3 Japan Dolutegravir and Its Combination Drug Market Size, 2017-2028
        6.5.4 South Korea Dolutegravir and Its Combination Drug Market Size, 2017-2028
        6.5.5 Southeast Asia Dolutegravir and Its Combination Drug Market Size, 2017-2028
        6.5.6 India Dolutegravir and Its Combination Drug Market Size, 2017-2028
    6.6 South America
        6.6.1 By Country - South America Dolutegravir and Its Combination Drug Revenue, 2017-2028
        6.6.2 Brazil Dolutegravir and Its Combination Drug Market Size, 2017-2028
        6.6.3 Argentina Dolutegravir and Its Combination Drug Market Size, 2017-2028
    6.7 Middle East & Africa
        6.7.1 By Country - Middle East & Africa Dolutegravir and Its Combination Drug Revenue, 2017-2028
        6.7.2 Turkey Dolutegravir and Its Combination Drug Market Size, 2017-2028
        6.7.3 Israel Dolutegravir and Its Combination Drug Market Size, 2017-2028
        6.7.4 Saudi Arabia Dolutegravir and Its Combination Drug Market Size, 2017-2028
        6.7.5 UAE Dolutegravir and Its Combination Drug Market Size, 2017-2028
7 Players Profiles
    7.1 ViiV Healthcare (GSK)
        7.1.1 ViiV Healthcare (GSK) Corporate Summary
        7.1.2 ViiV Healthcare (GSK) Business Overview
        7.1.3 ViiV Healthcare (GSK) Dolutegravir and Its Combination Drug Major Product Offerings
        7.1.4 ViiV Healthcare (GSK) Dolutegravir and Its Combination Drug Revenue in Global Market (2017-2022)
        7.1.5 ViiV Healthcare (GSK) Key News
    7.2 Adcock Ingram Limited
        7.2.1 Adcock Ingram Limited Corporate Summary
        7.2.2 Adcock Ingram Limited Business Overview
        7.2.3 Adcock Ingram Limited Dolutegravir and Its Combination Drug Major Product Offerings
        7.2.4 Adcock Ingram Limited Dolutegravir and Its Combination Drug Revenue in Global Market (2017-2022)
        7.2.5 Adcock Ingram Limited Key News
    7.3 Aurobindo Pharma
        7.3.1 Aurobindo Pharma Corporate Summary
        7.3.2 Aurobindo Pharma Business Overview
        7.3.3 Aurobindo Pharma Dolutegravir and Its Combination Drug Major Product Offerings
        7.3.4 Aurobindo Pharma Dolutegravir and Its Combination Drug Revenue in Global Market (2017-2022)
        7.3.5 Aurobindo Pharma Key News
    7.4 Cipla
        7.4.1 Cipla Corporate Summary
        7.4.2 Cipla Business Overview
        7.4.3 Cipla Dolutegravir and Its Combination Drug Major Product Offerings
        7.4.4 Cipla Dolutegravir and Its Combination Drug Revenue in Global Market (2017-2022)
        7.4.5 Cipla Key News
    7.5 Emcure Pharmaceuticals
        7.5.1 Emcure Pharmaceuticals Corporate Summary
        7.5.2 Emcure Pharmaceuticals Business Overview
        7.5.3 Emcure Pharmaceuticals Dolutegravir and Its Combination Drug Major Product Offerings
        7.5.4 Emcure Pharmaceuticals Dolutegravir and Its Combination Drug Revenue in Global Market (2017-2022)
        7.5.5 Emcure Pharmaceuticals Key News
    7.6 LAURUS Labs
        7.6.1 LAURUS Labs Corporate Summary
        7.6.2 LAURUS Labs Business Overview
        7.6.3 LAURUS Labs Dolutegravir and Its Combination Drug Major Product Offerings
        7.6.4 LAURUS Labs Dolutegravir and Its Combination Drug Revenue in Global Market (2017-2022)
        7.6.5 LAURUS Labs Key News
    7.7 Mylan
        7.7.1 Mylan Corporate Summary
        7.7.2 Mylan Business Overview
        7.7.3 Mylan Dolutegravir and Its Combination Drug Major Product Offerings
        7.7.4 Mylan Dolutegravir and Its Combination Drug Revenue in Global Market (2017-2022)
        7.7.5 Mylan Key News
    7.8 Ranbaxy Pharmaceuticals
        7.8.1 Ranbaxy Pharmaceuticals Corporate Summary
        7.8.2 Ranbaxy Pharmaceuticals Business Overview
        7.8.3 Ranbaxy Pharmaceuticals Dolutegravir and Its Combination Drug Major Product Offerings
        7.8.4 Ranbaxy Pharmaceuticals Dolutegravir and Its Combination Drug Revenue in Global Market (2017-2022)
        7.8.5 Ranbaxy Pharmaceuticals Key News
    7.9 Shanghai Desano Pharmaceuticals
        7.9.1 Shanghai Desano Pharmaceuticals Corporate Summary
        7.9.2 Shanghai Desano Pharmaceuticals Business Overview
        7.9.3 Shanghai Desano Pharmaceuticals Dolutegravir and Its Combination Drug Major Product Offerings
        7.9.4 Shanghai Desano Pharmaceuticals Dolutegravir and Its Combination Drug Revenue in Global Market (2017-2022)
        7.9.5 Shanghai Desano Pharmaceuticals Key News
    7.10 JNJ
        7.10.1 JNJ Corporate Summary
        7.10.2 JNJ Business Overview
        7.10.3 JNJ Dolutegravir and Its Combination Drug Major Product Offerings
        7.10.4 JNJ Dolutegravir and Its Combination Drug Revenue in Global Market (2017-2022)
        7.10.5 JNJ Key News
8 Conclusion
9 Appendix
    9.1 Note
    9.2 Examples of Clients
    9.3 Disclaimer

List of Tables
    Table 1. Dolutegravir and Its Combination Drug Market Opportunities & Trends in Global Market
    Table 2. Dolutegravir and Its Combination Drug Market Drivers in Global Market
    Table 3. Dolutegravir and Its Combination Drug Market Restraints in Global Market
    Table 4. Key Players of Dolutegravir and Its Combination Drug in Global Market
    Table 5. Top Dolutegravir and Its Combination Drug Players in Global Market, Ranking by Revenue (2021)
    Table 6. Global Dolutegravir and Its Combination Drug Revenue by Companies, (US$, Mn), 2017-2022
    Table 7. Global Dolutegravir and Its Combination Drug Revenue Share by Companies, 2017-2022
    Table 8. Global Companies Dolutegravir and Its Combination Drug Product Type
    Table 9. List of Global Tier 1 Dolutegravir and Its Combination Drug Companies, Revenue (US$, Mn) in 2021 and Market Share
    Table 10. List of Global Tier 2 and Tier 3 Dolutegravir and Its Combination Drug Companies, Revenue (US$, Mn) in 2021 and Market Share
    Table 11. By Type – Global Dolutegravir and Its Combination Drug Revenue, (US$, Mn), 2021 & 2028
    Table 12. By Type - Dolutegravir and Its Combination Drug Revenue in Global (US$, Mn), 2017-2022
    Table 13. By Type - Dolutegravir and Its Combination Drug Revenue in Global (US$, Mn), 2023-2028
    Table 14. By Application – Global Dolutegravir and Its Combination Drug Revenue, (US$, Mn), 2021 & 2028
    Table 15. By Application - Dolutegravir and Its Combination Drug Revenue in Global (US$, Mn), 2017-2022
    Table 16. By Application - Dolutegravir and Its Combination Drug Revenue in Global (US$, Mn), 2023-2028
    Table 17. By Region – Global Dolutegravir and Its Combination Drug Revenue, (US$, Mn), 2021 & 2028
    Table 18. By Region - Global Dolutegravir and Its Combination Drug Revenue (US$, Mn), 2017-2022
    Table 19. By Region - Global Dolutegravir and Its Combination Drug Revenue (US$, Mn), 2023-2028
    Table 20. By Country - North America Dolutegravir and Its Combination Drug Revenue, (US$, Mn), 2017-2022
    Table 21. By Country - North America Dolutegravir and Its Combination Drug Revenue, (US$, Mn), 2023-2028
    Table 22. By Country - Europe Dolutegravir and Its Combination Drug Revenue, (US$, Mn), 2017-2022
    Table 23. By Country - Europe Dolutegravir and Its Combination Drug Revenue, (US$, Mn), 2023-2028
    Table 24. By Region - Asia Dolutegravir and Its Combination Drug Revenue, (US$, Mn), 2017-2022
    Table 25. By Region - Asia Dolutegravir and Its Combination Drug Revenue, (US$, Mn), 2023-2028
    Table 26. By Country - South America Dolutegravir and Its Combination Drug Revenue, (US$, Mn), 2017-2022
    Table 27. By Country - South America Dolutegravir and Its Combination Drug Revenue, (US$, Mn), 2023-2028
    Table 28. By Country - Middle East & Africa Dolutegravir and Its Combination Drug Revenue, (US$, Mn), 2017-2022
    Table 29. By Country - Middle East & Africa Dolutegravir and Its Combination Drug Revenue, (US$, Mn), 2023-2028
    Table 30. ViiV Healthcare (GSK) Corporate Summary
    Table 31. ViiV Healthcare (GSK) Dolutegravir and Its Combination Drug Product Offerings
    Table 32. ViiV Healthcare (GSK) Dolutegravir and Its Combination Drug Revenue (US$, Mn), (2017-2022)
    Table 33. Adcock Ingram Limited Corporate Summary
    Table 34. Adcock Ingram Limited Dolutegravir and Its Combination Drug Product Offerings
    Table 35. Adcock Ingram Limited Dolutegravir and Its Combination Drug Revenue (US$, Mn), (2017-2022)
    Table 36. Aurobindo Pharma Corporate Summary
    Table 37. Aurobindo Pharma Dolutegravir and Its Combination Drug Product Offerings
    Table 38. Aurobindo Pharma Dolutegravir and Its Combination Drug Revenue (US$, Mn), (2017-2022)
    Table 39. Cipla Corporate Summary
    Table 40. Cipla Dolutegravir and Its Combination Drug Product Offerings
    Table 41. Cipla Dolutegravir and Its Combination Drug Revenue (US$, Mn), (2017-2022)
    Table 42. Emcure Pharmaceuticals Corporate Summary
    Table 43. Emcure Pharmaceuticals Dolutegravir and Its Combination Drug Product Offerings
    Table 44. Emcure Pharmaceuticals Dolutegravir and Its Combination Drug Revenue (US$, Mn), (2017-2022)
    Table 45. LAURUS Labs Corporate Summary
    Table 46. LAURUS Labs Dolutegravir and Its Combination Drug Product Offerings
    Table 47. LAURUS Labs Dolutegravir and Its Combination Drug Revenue (US$, Mn), (2017-2022)
    Table 48. Mylan Corporate Summary
    Table 49. Mylan Dolutegravir and Its Combination Drug Product Offerings
    Table 50. Mylan Dolutegravir and Its Combination Drug Revenue (US$, Mn), (2017-2022)
    Table 51. Ranbaxy Pharmaceuticals Corporate Summary
    Table 52. Ranbaxy Pharmaceuticals Dolutegravir and Its Combination Drug Product Offerings
    Table 53. Ranbaxy Pharmaceuticals Dolutegravir and Its Combination Drug Revenue (US$, Mn), (2017-2022)
    Table 54. Shanghai Desano Pharmaceuticals Corporate Summary
    Table 55. Shanghai Desano Pharmaceuticals Dolutegravir and Its Combination Drug Product Offerings
    Table 56. Shanghai Desano Pharmaceuticals Dolutegravir and Its Combination Drug Revenue (US$, Mn), (2017-2022)
    Table 57. JNJ Corporate Summary
    Table 58. JNJ Dolutegravir and Its Combination Drug Product Offerings
    Table 59. JNJ Dolutegravir and Its Combination Drug Revenue (US$, Mn), (2017-2022)
List of Figures
    Figure 1. Dolutegravir and Its Combination Drug Segment by Type in 2021
    Figure 2. Dolutegravir and Its Combination Drug Segment by Application in 2021
    Figure 3. Global Dolutegravir and Its Combination Drug Market Overview: 2021
    Figure 4. Key Caveats
    Figure 5. Global Dolutegravir and Its Combination Drug Market Size: 2021 VS 2028 (US$, Mn)
    Figure 6. Global Dolutegravir and Its Combination Drug Revenue, 2017-2028 (US$, Mn)
    Figure 7. The Top 3 and 5 Players Market Share by Dolutegravir and Its Combination Drug Revenue in 2021
    Figure 8. By Type - Global Dolutegravir and Its Combination Drug Revenue Market Share, 2017-2028
    Figure 9. By Application - Global Dolutegravir and Its Combination Drug Revenue Market Share, 2017-2028
    Figure 10. By Region - Global Dolutegravir and Its Combination Drug Revenue Market Share, 2017-2028
    Figure 11. By Country - North America Dolutegravir and Its Combination Drug Revenue Market Share, 2017-2028
    Figure 12. US Dolutegravir and Its Combination Drug Revenue, (US$, Mn), 2017-2028
    Figure 13. Canada Dolutegravir and Its Combination Drug Revenue, (US$, Mn), 2017-2028
    Figure 14. Mexico Dolutegravir and Its Combination Drug Revenue, (US$, Mn), 2017-2028
    Figure 15. By Country - Europe Dolutegravir and Its Combination Drug Revenue Market Share, 2017-2028
    Figure 16. Germany Dolutegravir and Its Combination Drug Revenue, (US$, Mn), 2017-2028
    Figure 17. France Dolutegravir and Its Combination Drug Revenue, (US$, Mn), 2017-2028
    Figure 18. U.K. Dolutegravir and Its Combination Drug Revenue, (US$, Mn), 2017-2028
    Figure 19. Italy Dolutegravir and Its Combination Drug Revenue, (US$, Mn), 2017-2028
    Figure 20. Russia Dolutegravir and Its Combination Drug Revenue, (US$, Mn), 2017-2028
    Figure 21. Nordic Countries Dolutegravir and Its Combination Drug Revenue, (US$, Mn), 2017-2028
    Figure 22. Benelux Dolutegravir and Its Combination Drug Revenue, (US$, Mn), 2017-2028
    Figure 23. By Region - Asia Dolutegravir and Its Combination Drug Revenue Market Share, 2017-2028
    Figure 24. China Dolutegravir and Its Combination Drug Revenue, (US$, Mn), 2017-2028
    Figure 25. Japan Dolutegravir and Its Combination Drug Revenue, (US$, Mn), 2017-2028
    Figure 26. South Korea Dolutegravir and Its Combination Drug Revenue, (US$, Mn), 2017-2028
    Figure 27. Southeast Asia Dolutegravir and Its Combination Drug Revenue, (US$, Mn), 2017-2028
    Figure 28. India Dolutegravir and Its Combination Drug Revenue, (US$, Mn), 2017-2028
    Figure 29. By Country - South America Dolutegravir and Its Combination Drug Revenue Market Share, 2017-2028
    Figure 30. Brazil Dolutegravir and Its Combination Drug Revenue, (US$, Mn), 2017-2028
    Figure 31. Argentina Dolutegravir and Its Combination Drug Revenue, (US$, Mn), 2017-2028
    Figure 32. By Country - Middle East & Africa Dolutegravir and Its Combination Drug Revenue Market Share, 2017-2028
    Figure 33. Turkey Dolutegravir and Its Combination Drug Revenue, (US$, Mn), 2017-2028
    Figure 34. Israel Dolutegravir and Its Combination Drug Revenue, (US$, Mn), 2017-2028
    Figure 35. Saudi Arabia Dolutegravir and Its Combination Drug Revenue, (US$, Mn), 2017-2028
    Figure 36. UAE Dolutegravir and Its Combination Drug Revenue, (US$, Mn), 2017-2028
    Figure 37. ViiV Healthcare (GSK) Dolutegravir and Its Combination Drug Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 38. Adcock Ingram Limited Dolutegravir and Its Combination Drug Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 39. Aurobindo Pharma Dolutegravir and Its Combination Drug Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 40. Cipla Dolutegravir and Its Combination Drug Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 41. Emcure Pharmaceuticals Dolutegravir and Its Combination Drug Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 42. LAURUS Labs Dolutegravir and Its Combination Drug Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 43. Mylan Dolutegravir and Its Combination Drug Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 44. Ranbaxy Pharmaceuticals Dolutegravir and Its Combination Drug Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 45. Shanghai Desano Pharmaceuticals Dolutegravir and Its Combination Drug Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 46. JNJ Dolutegravir and Its Combination Drug Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
64
Frequently Asked Questions
Dolutegravir and Its Combination Drug Market report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Dolutegravir and Its Combination Drug Market report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Dolutegravir and Its Combination Drug Market report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports

Letrozole Market

This report contains market size and forecasts of Letrozole in global, including the following ma ... Read More

Tamoxifen Market

This report contains market size and forecasts of Tamoxifen in global, including the following ma ... Read More